Piper (Drug Discovery) Overview

  • Founded
  • 2015
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

Piper (Drug Discovery) General Information


Developer of medical therapies intended to offer drugs focusing on the immune and inflammatory response. The company's therapies promote a microenvironment to inhibit tumour growth, slow sepsis, and calm autoimmune disease, enabling healthcare professionals to offer advanced and quick medical help to their patients.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • One Broadway
  • 14th Floor
  • Cambridge, MA 02142
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Piper (Drug Discovery) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 01-Jun-2019 00.00 Completed Out of Business
2. Accelerator/Incubator 13-Oct-2016 000 00.00 Completed Generating Revenue
1. Seed Round 19-May-2016 $1.3M $1.3M 00.00 Completed Generating Revenue
To view Piper (Drug Discovery)’s complete valuation and funding history, request access »

Piper (Drug Discovery) Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Piper (Drug Discovery)’s complete cap table history, request access »